tetano
Editor, Senior Moderator
Inflammopharmacology
. 2022 Jun 20.
doi: 10.1007/s10787-022-01001-2. Online ahead of print.
Evaluating the effect of Edaravone on clinical outcome of patients with severe COVID-19 admitted to ICU: a randomized clinical trial
Mohammadreza Moslemi[SUP] 1 2 [/SUP], Seyyedeh Mina Hejazian[SUP] 1 2 [/SUP], Molod Shaddelan[SUP] 2 [/SUP], Fatemeh Javanali[SUP] 2 [/SUP], Alireza Mirghaffari[SUP] 2 [/SUP], Armin Sadeghi[SUP] 3 [/SUP], Hamed Valizadeh[SUP] 3 [/SUP], Akbar Sharifi[SUP] 3 [/SUP], Morteza Haramshahi[SUP] 2 [/SUP], Mohammadreza Ardalan[SUP] 4 [/SUP], Sepideh Zununi Vahed[SUP] 5 [/SUP]
Affiliations
Abstract
Cytokine storm is the most prominent hallmark in patients with coronavirus disease 2019 (COVID-19) that stimulates the free radical storm, both of which induce an overactive immune response during viral infection. We hypothesized that owning to its radical-scavenging and anti-inflammatory properties, Edaravone could reduce multi-organ injury, clinical complications, and mortality in severe COVID-19 cases. This single-center randomized clinical trial was accompanied in the intensive care units (ICUs) of the teaching hospital of Tabriz University of Medical Sciences to evaluate the effect of Edaravone on the outcome of patients with severe COVID-19. Thirty-eight patients admitted to ICU were included and randomized into two control and intervention arms. Patients in the intervention group received 30 mg Edaravone by slow intravenous infusion for three days in addition to receiving national therapy. The primary outcome was the need for intubation, the intubation length, and mortality rate. Secondary endpoints were clinical improvement. Edaravone administration improved the primary outcomes; it decreased the need for endotracheal intubation and mechanical ventilation [10.52% (n = 2) versus 42.1% (n = 8); p = 0.03] and intubation length [3 (1-7) versus 28 (4-28), p = 0.04] compared to control group. Baseline characteristics and laboratory tests were similar between the studied groups. No marked differences were observed in secondary endpoints (p > 0.05). Administration of Edaravone could decrease the need for mechanical ventilation and length of intubation in severe COVID-19 patients admitted to ICU.
Keywords: Antioxidant; COVID-19; Edaravone; Pneumonia; mechanical ventilation.
. 2022 Jun 20.
doi: 10.1007/s10787-022-01001-2. Online ahead of print.
Evaluating the effect of Edaravone on clinical outcome of patients with severe COVID-19 admitted to ICU: a randomized clinical trial
Mohammadreza Moslemi[SUP] 1 2 [/SUP], Seyyedeh Mina Hejazian[SUP] 1 2 [/SUP], Molod Shaddelan[SUP] 2 [/SUP], Fatemeh Javanali[SUP] 2 [/SUP], Alireza Mirghaffari[SUP] 2 [/SUP], Armin Sadeghi[SUP] 3 [/SUP], Hamed Valizadeh[SUP] 3 [/SUP], Akbar Sharifi[SUP] 3 [/SUP], Morteza Haramshahi[SUP] 2 [/SUP], Mohammadreza Ardalan[SUP] 4 [/SUP], Sepideh Zununi Vahed[SUP] 5 [/SUP]
Affiliations
- PMID: 35723849
- DOI: 10.1007/s10787-022-01001-2
Abstract
Cytokine storm is the most prominent hallmark in patients with coronavirus disease 2019 (COVID-19) that stimulates the free radical storm, both of which induce an overactive immune response during viral infection. We hypothesized that owning to its radical-scavenging and anti-inflammatory properties, Edaravone could reduce multi-organ injury, clinical complications, and mortality in severe COVID-19 cases. This single-center randomized clinical trial was accompanied in the intensive care units (ICUs) of the teaching hospital of Tabriz University of Medical Sciences to evaluate the effect of Edaravone on the outcome of patients with severe COVID-19. Thirty-eight patients admitted to ICU were included and randomized into two control and intervention arms. Patients in the intervention group received 30 mg Edaravone by slow intravenous infusion for three days in addition to receiving national therapy. The primary outcome was the need for intubation, the intubation length, and mortality rate. Secondary endpoints were clinical improvement. Edaravone administration improved the primary outcomes; it decreased the need for endotracheal intubation and mechanical ventilation [10.52% (n = 2) versus 42.1% (n = 8); p = 0.03] and intubation length [3 (1-7) versus 28 (4-28), p = 0.04] compared to control group. Baseline characteristics and laboratory tests were similar between the studied groups. No marked differences were observed in secondary endpoints (p > 0.05). Administration of Edaravone could decrease the need for mechanical ventilation and length of intubation in severe COVID-19 patients admitted to ICU.
Keywords: Antioxidant; COVID-19; Edaravone; Pneumonia; mechanical ventilation.